Cargando…
A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1
PURPOSE: WHO recommends dolutegravir (DTG) based regimens as first-line treatment for HIV-1 infection. However, few studies have been conducted in Indian population. Hence, our study evaluated the safety, tolerability, and efficacy of DTG 50 mg with Tenofovir and Lamivudine (300/300mg) fixed dose co...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375976/ https://www.ncbi.nlm.nih.gov/pubmed/35975180 http://dx.doi.org/10.2147/POR.S361907 |
_version_ | 1784768063779897344 |
---|---|
author | Dravid, Ameet Morkar, Dnyanesh Prasad, Dwijendra Ramapuram, John T Patel, Kartik Vikrambhai Naik, K Sunil Bhrusundi, Milind Kulkarni, Milind Hegde, Sanjeev Anuradha, S Nageswaramma, Siddabathuni Madan, Surabhi Jayaprakash, Thammisetty Kulkarni, Vinay |
author_facet | Dravid, Ameet Morkar, Dnyanesh Prasad, Dwijendra Ramapuram, John T Patel, Kartik Vikrambhai Naik, K Sunil Bhrusundi, Milind Kulkarni, Milind Hegde, Sanjeev Anuradha, S Nageswaramma, Siddabathuni Madan, Surabhi Jayaprakash, Thammisetty Kulkarni, Vinay |
author_sort | Dravid, Ameet |
collection | PubMed |
description | PURPOSE: WHO recommends dolutegravir (DTG) based regimens as first-line treatment for HIV-1 infection. However, few studies have been conducted in Indian population. Hence, our study evaluated the safety, tolerability, and efficacy of DTG 50 mg with Tenofovir and Lamivudine (300/300mg) fixed dose combination in treatment naïve adult Indian patients. METHODS: This was an open label, multicenter, prospective, interventional, phase IV study conducted across 14 sites between February 2019 and July 2020. 24 weeks was the treatment duration for each subject. The primary end point was to assess the incidence of adverse events (AEs) and secondary end points were to assess the proportion of patients achieving plasma HIV-1 RNA levels <50 copies/mL at week 24 and change in CD4+ cell count from the baseline. Safety analysis was conducted using Safety Analysis Set and efficacy analysis was carried out using Full Analysis Set and Per protocol set. RESULTS: A total of 288 patients were screened; 250 were enrolled; and 229 completed the study. 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. One event of decreased creatinine clearance led to study discontinuation. One serious event of pyrexia was reported, which was unrelated to the study drug. The most common AEs were headache (18%), pyrexia (14%), vomiting (6.4%) and upper respiratory tract infections (6%). No deaths were reported. At week 24, 86.8% of the patients achieved plasma HIV-1 RNA levels <50 copies/mL and the mean CD4 cell count increased from 350.2 (SD, 239.73) at baseline to 494.6 (SD, 261.40) with an average increase of 143.2 (SD, 226.14) cells. CONCLUSION: This study demonstrated the safety and efficacy of DTG based regimen in treatment naïve HIV-1 patients in Indian population and support use of DTG as first-line treatment regimen. |
format | Online Article Text |
id | pubmed-9375976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93759762022-08-15 A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 Dravid, Ameet Morkar, Dnyanesh Prasad, Dwijendra Ramapuram, John T Patel, Kartik Vikrambhai Naik, K Sunil Bhrusundi, Milind Kulkarni, Milind Hegde, Sanjeev Anuradha, S Nageswaramma, Siddabathuni Madan, Surabhi Jayaprakash, Thammisetty Kulkarni, Vinay Pragmat Obs Res Original Research PURPOSE: WHO recommends dolutegravir (DTG) based regimens as first-line treatment for HIV-1 infection. However, few studies have been conducted in Indian population. Hence, our study evaluated the safety, tolerability, and efficacy of DTG 50 mg with Tenofovir and Lamivudine (300/300mg) fixed dose combination in treatment naïve adult Indian patients. METHODS: This was an open label, multicenter, prospective, interventional, phase IV study conducted across 14 sites between February 2019 and July 2020. 24 weeks was the treatment duration for each subject. The primary end point was to assess the incidence of adverse events (AEs) and secondary end points were to assess the proportion of patients achieving plasma HIV-1 RNA levels <50 copies/mL at week 24 and change in CD4+ cell count from the baseline. Safety analysis was conducted using Safety Analysis Set and efficacy analysis was carried out using Full Analysis Set and Per protocol set. RESULTS: A total of 288 patients were screened; 250 were enrolled; and 229 completed the study. 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. One event of decreased creatinine clearance led to study discontinuation. One serious event of pyrexia was reported, which was unrelated to the study drug. The most common AEs were headache (18%), pyrexia (14%), vomiting (6.4%) and upper respiratory tract infections (6%). No deaths were reported. At week 24, 86.8% of the patients achieved plasma HIV-1 RNA levels <50 copies/mL and the mean CD4 cell count increased from 350.2 (SD, 239.73) at baseline to 494.6 (SD, 261.40) with an average increase of 143.2 (SD, 226.14) cells. CONCLUSION: This study demonstrated the safety and efficacy of DTG based regimen in treatment naïve HIV-1 patients in Indian population and support use of DTG as first-line treatment regimen. Dove 2022-08-10 /pmc/articles/PMC9375976/ /pubmed/35975180 http://dx.doi.org/10.2147/POR.S361907 Text en © 2022 Dravid et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Dravid, Ameet Morkar, Dnyanesh Prasad, Dwijendra Ramapuram, John T Patel, Kartik Vikrambhai Naik, K Sunil Bhrusundi, Milind Kulkarni, Milind Hegde, Sanjeev Anuradha, S Nageswaramma, Siddabathuni Madan, Surabhi Jayaprakash, Thammisetty Kulkarni, Vinay A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 |
title | A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 |
title_full | A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 |
title_fullStr | A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 |
title_full_unstemmed | A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 |
title_short | A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1 |
title_sort | phase iv study on safety, tolerability and efficacy of dolutegravir, lamivudine, and tenofovir disoproxil fumarate in treatment naïve adult indian patients living with hiv-1 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375976/ https://www.ncbi.nlm.nih.gov/pubmed/35975180 http://dx.doi.org/10.2147/POR.S361907 |
work_keys_str_mv | AT dravidameet aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT morkardnyanesh aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT prasaddwijendra aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT ramapuramjohnt aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT patelkartikvikrambhai aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT naikksunil aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT bhrusundimilind aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT kulkarnimilind aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT hegdesanjeev aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT anuradhas aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT nageswarammasiddabathuni aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT madansurabhi aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT jayaprakashthammisetty aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT kulkarnivinay aphaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT dravidameet phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT morkardnyanesh phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT prasaddwijendra phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT ramapuramjohnt phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT patelkartikvikrambhai phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT naikksunil phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT bhrusundimilind phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT kulkarnimilind phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT hegdesanjeev phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT anuradhas phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT nageswarammasiddabathuni phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT madansurabhi phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT jayaprakashthammisetty phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 AT kulkarnivinay phaseivstudyonsafetytolerabilityandefficacyofdolutegravirlamivudineandtenofovirdisoproxilfumarateintreatmentnaiveadultindianpatientslivingwithhiv1 |